Friday, October 04, 2024 12:10:28 PM
is pleased to announce that it will be presenting two posters at the SITC 2024 Annual Meeting.
The first poster presentation contains updated and expanded data from the complete cohort (n=31) from the first line (1L) cohort of patients with PD-L1 high metastatic non-small cell lung cancer (NSCLC) in our Phase 2 basket trial of investigational IO102-IO103 in combination with pembrolizumab (KEYTRUDA®), Merck’s anti-PD-1 therapy. The second poster presentation contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1.
We look forward to sharing these exciting data at the meeting which takes place in Houston from November 6-10, 2024. See full details here:
https://investors.iobiotech.com/news-events/news/news-details/2024/IO-Biotech-Announces-Two-Poster-Presentations-at-the-Society-for-Immunotherapy-of-Cancers-SITC-39th-Annual-Meeting/default.aspx
Recent IOBT News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2026 10:22:46 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/13/2026 10:06:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2026 09:53:41 PM
- IO Biotech Provides Corporate Update • GlobeNewswire Inc. • 01/30/2026 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/21/2026 11:05:41 AM
- IO Biotech Announces Exploration of Strategic Alternatives • GlobeNewswire Inc. • 01/21/2026 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2025 10:18:23 PM
- IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications • GlobeNewswire Inc. • 12/15/2025 09:05:00 PM
- IO Biotech Announces Participation in Upcoming December Investor Conferences • GlobeNewswire Inc. • 11/26/2025 03:46:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/21/2025 09:44:15 PM
- Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For • InvestorsHub NewsWire • 11/20/2025 02:00:00 PM
- Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For • GlobeNewswire Inc. • 11/20/2025 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/18/2025 11:30:19 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 02:10:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 01:10:14 PM
- IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights • GlobeNewswire Inc. • 11/14/2025 01:05:00 PM
- IO Biotech Announces Participation in Upcoming Investor Conferences • GlobeNewswire Inc. • 11/12/2025 01:30:00 PM
- IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) • GlobeNewswire Inc. • 11/07/2025 02:00:00 PM
- Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology • InvestorsHub NewsWire • 10/27/2025 01:00:00 PM
- Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology • PR Newswire (Canada) • 10/27/2025 12:30:00 PM
- Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology • PR Newswire (US) • 10/27/2025 12:30:00 PM
- IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025 • GlobeNewswire Inc. • 10/20/2025 06:30:00 AM
- Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion • PR Newswire (US) • 10/07/2025 01:00:00 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
